Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + fluorouracil + doxorubicin
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOD is a combination chemotherapy regimen comprising fluorouracil, oxaliplatin, and doxorubicin. It is primarily investigated as a neoadjuvant (preoperative) treatment for patients with locally advanced gastric cardia cancer, a specific type of esophageal or gastric adenocarcinoma. The regimen's efficacy is derived from the synergistic effects of its three components: fluorouracil, a pyrimidine analog antimetabolite that inhibits DNA synthesis; oxaliplatin, a third-generation platinum agent that creates DNA cross-links; and doxorubicin, an anthracycline that disrupts DNA repair and transcription by intercalating into DNA and inhibiting topoisomerase II. Research conducted by The First Affiliated Hospital of Zhengzhou University has focused on using this combination to downstage tumors and improve the rate of complete surgical resection (R0 resection) in patients with cardia-located gastric malignancies.
- Other names
- FOD regimen5-fluorouracil + oxaliplatin + doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on oxaliplatin + fluorouracil + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + fluorouracil + doxorubicin.